Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
Scope of the Report:
The classification of drugs for malaria includes aryl aminoalcohol compounds, antifolate compounds and artemisinin compounds. The proportion of aryl aminoalcohol compounds drugs for malaria in 2016 is about 16.8%, the proportion of antifolate compounds in 2016 is about 55.4% and the proportion of artemisinin compounds in 2016 is about 27.8%.
Drugs for malaria are application in Preventioning malaria, curing malaria and other areas. The most of drugs for malaria is used in Preventioning malaria; the market share in 2016 is about 56.1%. And 35.1% of drugs for malaria are used in curing malaria.
Market competition is intense. The major manufacturers are Cipla, Guilin Pharmaceutical, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aventis and Ajanta Pharma in the United States.
The worldwide market for Drugs for Malaria is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Drugs for Malaria in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Aryl Aminoalcohol Compounds
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Malaria product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Malaria, with price, sales, revenue and global market share of Drugs for Malaria in 2017 and 2018.
Chapter 3, the Drugs for Malaria competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Malaria breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Drugs for Malaria market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Drugs for Malaria sales channel, distributors, customers, research findings and conclusion, appendix and data source.